Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03538756
Recruitment Status : Recruiting
First Posted : May 29, 2018
Last Update Posted : May 15, 2020
Sponsor:
Information provided by (Responsible Party):
RxFunction Inc.

Brief Summary:
The purpose of this study is to investigate the long-term effects of Walkasins® use on clinical and subject-reported outcomes of balance and gait function, quality of life, physical activity/participation, pain, and medication use in persons with peripheral neuropathy who experience balance problems.

Condition or disease Intervention/treatment Phase
Sensory Peripheral Neuropathy Balance; Distorted Sensation Disorders Device: Walkasins Not Applicable

Detailed Description:

The main objective of the current study is to show a long-term (10 weeks) sustained improvement in FGA score >4 following Walkasins use as compared to initial baseline assessment and to examine a potential relationship between initial baseline assessment data and long-term outcome. The finding of a short-term FGA change >4 during Walkasins use justifies a pre-post study design to investigate the long-term effects of walkasins use.

The investigators also intend to extend their observations of the short-term effects of walkasins by replicating the randomized cross-over design of a previous short-term study. (The replication will occur during the baseline visit.) This study will help to further refine the prescription criteria for Walkasins and determine whether the presence of a short-term response is indicative of long-term improvements or not.

A subset of 10 participants at the Harvard Medical School site will be enrolled in a pilot study to investigate possible structural and functional changes in cortical areas of the brain related to somatosensory connectivity using magnetic resonance imaging (MRI). Structural as well as functional MRI scans will be acquired at baseline and after 26 weeks of daily Walkasins use. An exploratory analysis of MRI data will be performed and related to functional clinical outcomes associated with Walkasins use over the same time period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: walk2Wellness: Long-term Use Effects of Walkasins® Wearable Sensory Prosthesis on Gait Function, Balance-Confidence, and Social Participation
Actual Study Start Date : October 22, 2018
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2022

Arm Intervention/treatment
Experimental: Group A--Walkasins On Then Off

Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.

After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits.

Device: Walkasins
Walkasins® consist of two parts for each leg: the leg unit and the foot pad. The leg unit wraps around the lower leg of the user and contains electronics for reading foot pad pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.

Experimental: Group B--Walkasins Off Then On

Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.

After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits.

Device: Walkasins
Walkasins® consist of two parts for each leg: the leg unit and the foot pad. The leg unit wraps around the lower leg of the user and contains electronics for reading foot pad pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.




Primary Outcome Measures :
  1. Improvement in Functional Gait Assessment [ Time Frame: 10 Weeks ]
    Subjects will show a sustained improvement of their Functional Gait Assessment (FGA) of at least 4 compared to their initial assessment.


Secondary Outcome Measures :
  1. 10-Meter Walk Test [ Time Frame: 10 Weeks ]
    The investigators expect to see trends of increasing gait speed as assessed by the 10-meter Walk Test. (The middle 6 meters are timed.)

  2. Timed Up and Go Test (TUG) [ Time Frame: 10 Weeks ]
    The investigators expect to see improvement in subjects' performance in the Timed Up and Go Test, which is part of the CDC-recommended STEADI test protocol for balance function. The tester will record the time taken from the command "Go" until the subject sits down again.

  3. Four-Stage Balance Test [ Time Frame: 10 Weeks ]
    The 4-Stage Balance Test is part of the CDC-recommended test protocol for balance function. It includes four gradually more challenging postures the subject is exposed to.

  4. PHQ-9 [ Time Frame: 10 Weeks ]
    Subjects will complete the PHQ-9 to assess their emotional well-being.

  5. PROMIS Pain Interference Short Form 6b [ Time Frame: 10 Weeks ]
    Subjects will complete the Pain Interference Short Form 6b to determine how much their pain interferes will their activities.

  6. PROMIS Pain Intensity Form 1a [ Time Frame: 10 Weeks ]
    The PROMIS Pain Intensity instrument assesses how much a person hurts.

  7. PROMIS Ability to Participate Short Form 8a [ Time Frame: 10 Weeks ]
    The PROMIS Ability to Participate in Social Roles and Activities assesses the perceived ability to perform one's usual social roles and activities.

  8. PROMIS Satisfaction with Participation in Social Roles Short Form 8a [ Time Frame: 10 Weeks ]
    The PROMIS Satisfaction with Social Roles and Activities items assess satisfaction with performing one's usual social roles and activities (e.g., "I am satisfied with my ability to participate in family activities").

  9. Falls [ Time Frame: 10 Weeks ]
    Subjects will be asked about the number of times they have fallen in the past 6 and 12 months and whether they incurred an injury from falling. These data will be compared to falls during their participation in the trial as tracked with a calendar and reported as adverse events. Falls data will be monitored as overall number of fallers pre-and post-study participation as well as the number of falls/1000 patient days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 18-90 years, male or female
  • Formal diagnosis of sensory peripheral neuropathy prior to participating in the study
  • Self-reported balance problems
  • Ability for transfers or ambulation on level surfaces at fixed cadence as assessed by the physical therapist during the FGA
  • FGA <23, the cut-off score for high fall-risk
  • Ability to understand and provide informed consent
  • Foot size that allows Walkasins® to function appropriately
  • Must be able to complete all functional outcome measures without the use of an assistive device

Exclusion Criteria:

  • Inability to perceive vibration from Walkasins leg unit
  • Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins
  • Acute thrombophlebitis including deep vein thrombosis
  • Untreated lymphedema
  • Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use
  • Untreated fractures in the foot and ankle
  • Severe peripheral vascular disease
  • Musculoskeletal or other neurological conditions that prohibit use of Walkasins as determined by clinician
  • Weighs more than 300 pounds
  • Plans to begin balance physical therapy (PT) during the first ten weeks of the clinical trial (Ongoing or previous balance PT is not an exclusionary criterion.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03538756


Contacts
Layout table for location contacts
Contact: Lars Oddsson, PhD 612-358-2140 loddsson@rxfunction.com
Contact: Customer Service 612-358-2225 info@rxfunction.com

Locations
Layout table for location information
United States, Maryland
Johns Hopkins School of Medicine Recruiting
Baltimore, Maryland, United States, 21287
Contact: Jing Ye    410-955-0938    jye23@jhmi.edu   
Contact: Mohammad Khoshnoodi, MD       mkhoshn1@jhmi.edu   
Principal Investigator: Mohammad Khoshnoodi, MD         
United States, Massachusetts
Marcus Institute for Aging Research, Harvard Medical School Recruiting
Boston, Massachusetts, United States, 02131
Contact: Lewis A. Lipsitz, MD    617-971-5318    Lipsitz@hsl.harvard.edu   
Contact: Brad Manor, PhD    617-971-5332    BradManor@hsl.harvard.edu   
Principal Investigator: Lewis A. Lipsitz, MD         
United States, Minnesota
Minneapolis VA Health Care System Active, not recruiting
Minneapolis, Minnesota, United States, 55417
Fairview Health Services Recruiting
Saint Paul, Minnesota, United States, 55114
Contact: Teresa Bisson, DPT    612-273-6510    tbisson2@Fairview.org   
Contact: Front Desk    612-273-3868      
Principal Investigator: Teresa Bisson, DPT         
United States, Texas
Baylor College of Medicine Active, not recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
RxFunction Inc.
Investigators
Layout table for investigator information
Study Director: Lars Oddsson, PhD RxFunction Inc.
Additional Information:
Layout table for additonal information
Responsible Party: RxFunction Inc.
ClinicalTrials.gov Identifier: NCT03538756    
Other Study ID Numbers: CIP-0002 & CIP-0003
First Posted: May 29, 2018    Key Record Dates
Last Update Posted: May 15, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by RxFunction Inc.:
Balance
Peripheral Neuropathy
Neuropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Sensation Disorders
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms